Summary Flavone acetic acid (FAA) was administered at a dose of 4.8 g m2 over 1 h to patients with advanced malignant disease in combination with Interleukin II. A new high performance liquid chromatography method is described to determine both the parent compound and eight drug-related products, and the conditions required to determine these components in plasma are discussed. The half-life over the first 8 h was 2.3 h, but the terminal clearance of the drug was extremely slow. Severe (WHO Grade 4) hypotension was observed in some patients. However, incidence of this did not appear to be associated with any differences in FAA plasma concentrations, nor were there differences in FAA clearance between those patients whose tumour responded to the drug combination and those who did not. (Hawarth, 1993; Thomsen, 1992) .
Flavone acetic acid (FAA) is a flavonoid which has been found to have high activity against solid murine tumours (Plowman et al., 1986) , although it is inactive against leukaemias and is not directly cytotoxic in vitro (Bibby et al., 1987) . In a murine renal carcinoma model, it has been shown to have a synergistic antitumour effect when combined with Interleukin 2(rIL-2) (Wiltrout et al., 1988) , which may indicate an involvement of immune effector cells. However, it is possible that metabolism of FAA is required for its action, and Chabot et al. (1989) have reported the occurrence of cytotoxic metabolites of FAA. A phase I trial of weekly 1 h infusions of FAA combined with 5 day infusions of recombinant human rIL-2 has been performed, and this paper describes the effect of rIL-2 on FAA metabolism and investigates whether the toxicity observed correlates with any changes in FAA pharmacokinetics or metabolism. A new HPLC method for the measurement of FAA and its metabolites is also presented, since published methods (Bibby et al., 1987; Chabot et al., 1989; Chabot & Gouyette, 1991; Cummings et al., 1988; Damia et al., 1990; Kerr et al., 1987) (Hawarth, 1993; Thomsen, 1992) .
Results
Chromatography A chromatogram of a human plasma sample taken 4 h after the start of infusion of FAA is shown in Figure 1 , and
illustrates the large number of drug-related peaks resolved. The first peak is labelled Ml + M2 since it does in fact comprise two components. This is shown in Figure 2 where the peak has been collected and injected into the low pH eluent, which resolves it into two peaks. The stability of the main metabolite M4 was also studied under various conditions following collection of the peak. At pH6.5 (th pH of the eluent), after 20 h at room temperature, -40% of the peak was lost, with the majority going to M5 -8 and a small amount converted back to FAA. Incubation with P- obtained, was 2370 ± 130 (Lg ml-') h (s.e.). There appeared to be no significant changes in the kinetics of FAA clearance or glucuronide production during the course of treatment, nor differences between those patients who responded to treatment and those who did not. However, the responder in Figure 4 , who was one of only four patients to receive five or Time (min) Figure 5 Figure 6 shows the maximum WHO grade of hypotension observed for each course plotted against the concentration of FAA at 2 h after the start of infusion. There was no correlation between these two parameters: a line fitted to the data had a slope which did not differ significantly from Maximum WHO grade hypotension Figure 6 WHO grade of hypotension and plasma FAA concentration 2 h after the start of infusion.
Discussion
Previous methods for the analysis of FAA have relied on extraction into an organic solvent such as chloroform (Damia et al., 1990; Kerr et al., 1987; Staubus et al., 1987) or the use of solid phase extraction columns (Cummings et al., 1988) . Both of these techniques may result in loss of polar metabolites which, in the absence of pure standards, may be difficult to quantify. Because the concentration of FAA is relatively high at the doses used, we chose a very simple protein precipitation technique using methanol, following addition of ammonium acetate, pH 5.5 to improve stability of the metabolites (Cummings et al., 1988) . In order to achieve the separation of the products seen in both the mouse and man by HPLC, we also found a solvent gradient to be essential. For this reason, we chose to use hesperetin as internal standard rather than hesperidin, since the latter elutes rather close to the drug-related peaks, and the more hydrophobic hesperetin was readily eluted by the gradient. Use of the ion-pairing reagent TBA, coupled with a relatively high pH6.5, enabled us to achieve the best separation apart from Ml + M2. Initially, we experimented with lower pH eluents without ion-pairing, using acetate, similar to those previously described (Cummings et al., 1988) , but despite the improved resolution of MI + M2, overall the separation was less satisfactory. The stability studies extend those of Cummings et al. (1989) and more particularly the recent work of Chabot and Gouyette (1991) , although the latter reported only two products. The peaks M5-8 are presumably the rearrangement products of the glucuronide as described by Chabot, although we detected four discrete peaks, in addition to MI + M2, the latter apparently also being related to the glucuronide, since high pH incubation (pH9.0) results in the appearance of the glucuronide-related M5-8. However, the conditions necessary for the formation of M1 + M2 remain unclear since they were only produced in the presence of plasma. M9 is presumably the FAA methylester formed by the reaction of methanol with the glucuronide as described by Chabot and Gouyette (1991) . This is a potentially serious source of error in determining the original glucuronide concentration if this peak is not eluted during an isocratic separation. Because it has an identical absorption spectrum to the glucuronide (Chabot & Gouyette, 1991) , the original concentration can be determined by summing the individual components. We also experimented with the use of acetonitrile as the protein precipitant instead of methanol. This competely eliminated the problem of ester formation, but gave slightly lower recovery of FAA (-85%) compared to methanol (-100%).
Although it would appear that the glucuronide M4 is the only true metabolite of FAA produced in either man or the mouse, the rearrangement products are almost certainly formed in vivo since we could never measure just M4 alone, even if the blood samples were immediately cooled, spun, extracted and analysed within 30 min of sampling, although further interconversion undoubtedly takes place if samples are not processed quickly.
The half-life of 2.3 h, measured in patients over the first 8 h following 4.8 g m-2 FAA, was very similar to that observed by Kerr et al. (1987) . After 8 h, elimination of FAA from plasma appeared to be slower but we have not attempted to calculate a rate constant since there were insufficient data points between 8 h and 20 h. However, fitting the data in a similar way to that of Kerr et al. (1987) between 8-24 h would give a half-life of approximately 4 h, comparable to the 4.1 h reported by these workers. Limited data which we have for later time points support the observation of Damia et al. (1990) , who showed very slow clearance with a terminal half-life of up to 24 h. Differences in the pharmacokinetics do not appear to predict the response to the combination of FAA and IL2, nor the incidence of toxicity; this may instead depend on the cytokine or nitric oxide response of the individual patient.
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